natgillin/translations-raw huggingface dataset:
Rumænien SC Delos Impex 96 SRLStr Horia, Closca si Crisan, Otopeni judetul Ilfov 
SC Delos Impex 96 SRLStr Horia, Closca si Crisan, Otopeni judetul Ilfov
Frankrig LABORATOIRES BIOVE 3 RUE DE LORRAINE 62510 ARQUES 
LABORATOIRES BIOVE 3 RUE DE LORRAINE 62510 ARQUES France
For at bevare oralt tylosin som en effektiv behandling til andre aktuelt godkendte indikationer til svin bør unødig eksponering undgås. 
To maintain oral tylosin as an efficacious treatment for other currently authorised indications for pigs, unnecessary exposure should be avoided.
Foranstaltninger til risikohåndtering eller -begrænsning 
Risk management or mitigation measures
Af disse grunde kan anbefalinger om at nedsætte den indledende dosis i en udvidet behandlingsperiode ikke godtages. 
For similar reasons recommendations to reduce the initial dose for an extended treatment period are not acceptable.
Der findes imidlertid effektive alternativer (f.eks. pleuromutiliner) og da der er meget få udbrud med følsomme organismer, anses risikoen for inadækvat behandling for at overstige den mulige fordel ved at have en supplerende behandlingsmulighed i det usandsynlige tilfælde, hvor følsomheden bekræftes. 
However, effective alternatives are available (e.g. pleuromutilins) and, as there are very few susceptible outbreaks, the risk for inadequate treatment is deemed to outweigh the possible benefit of an additional treatment option in the unlikely event of confirmed susceptibility.
AniMed Service AG Liebochstrasse 9 8143 Dobl Østrig 
AniMed Service AG Liebochstrasse 9 8143 Dobl Austria
Til luftvejssygdom hos svin er tylosin som premix i øjeblikket ofte godkendt med højere dosis de første 2-3 uger, efterfulgt af en lavere dosis (typisk 40 % af initialdosis) i længere tid, ofte betegnet “hele risikoperioden”. 
With regard to respiratory disease in pigs, tylosin premix formulations are currently often authorised for treatment using a higher dose for the first two to three weeks of treatment followed by a lower dose (typically 40% of the initial dose) for an extended period of time, often stated as the ‘whole risk period'.
1 anfører CVMP om makrolider, at “der kan være behov for at gennemgå visse produktresuméer med henblik på at fastsætte en kortere godkendt behandlingsvarighed i tilfælde, hvor denne findes unødvendigt lang i forhold til sygdommens sværhed”. 
1, the CVMP recommendations on macrolides state that ‘there might be a need to review certain SPCs to reduce the approved treatment duration in cases where it is found unnecessarily long in relation to the severity of the disease'.
2320 Hoogstraten Belgien 
2320 Hoogstraten Belgium
Danmark ScanVet Animal Health A/S Kongevejen 66 
Denmark ScanVet Animal Health A/S Kongevejen 66
Langvarig eksponering af svin for tylosin er knyttet til risiko for udvikling af antimikrobiel resistens. 
Extended exposure of tylosin to pigs is related to risk for development of antimicrobial resistance.
Specifikke anbefalinger om kortere behandlingstid end tre uger bibeholdes. 
Specific treatment recommendations shorter than 3 weeks should be maintained.
Ipswich, Suffolk, IP7 6RD Det Forenede Kongerige 
Ipswich, Suffolk, IP7 6RD United Kingdom
Makrolider er kritisk vigtige antimikrobielle stoffer til svin, hvorfor unødig eksponering og deraf følgende yderligere resistens i målpatogener vil udgøre en alvorlig risiko for dyrs helbred. 
As macrolides are critically important antimicrobials for pigs, unnecessary exposure leading to further resistance in target animal pathogens would be a serious risk to animal health.
Da rRNA-operonet hos B. hyodysenteriae kun findes som en enkelt kopi, er mutation af en enkelt base tilstrækkelig til fremkomst af makrolidresistente kloner (Zuerner og Stanton (1994) 
Since for B. hyodysenteriae the rRNA operon exists in a single copy one single base mutation is sufficient to achieve macrolide resistant clones (Zuerner and Stanton (1994)
Tilsvarende blev der beskrevet næsten fuldstændig resistens in vitro af 32 isolater af Brachyspira fra Tjekkiet (Sperling et al. 
Similarly, almost complete in vitro resistance was reported among 32 Brachyspira isolates from the Czech Republic (Sperling et al. (2011))
D-30625 Hannover Tyskland 
D-30625 Hannover Germany
Tyskland bioptivet Tierarzneimittel GmbH & Co. 
Germany bioptivet Tierarzneimittel GmbH & Co.
Tylosin er et makrolidantibiotikum, der produceres af Streptomyces fradiae. 
Tylosin is a macrolide antibiotic which is produced by Streptomyces fradiae.
Priestley Road Basingstoke, RG24 9NL Det Forenede Kongerige 
Priestley Road Basingstoke, RG24 9NL United Kingdom
Desuden er langtidseksponering for lave doser af tylosin forbundet med stigning i antal resistente Campylobacter coli, og gruppemedicinering med antibiotika er en risikofaktor for udbredelse af meticillinresistente Staphylococcus aureus (MRSA) hos svin. 
In addition, long-term exposure to low doses of tylosin is associated with an increase in the number of resistant Campylobacter coli and group medication with antibiotics is a risk factor for spread of methicillinresistant Staphylococcus aureus (MRSA) in pigs.
Langvarige, vagt definerede behandlingsperioder udgør en resistensmæssig risiko og er ikke videnskabeligt forsvarlige på baggrund af sygdommens epidemiologi eller den nuværende bevidsthed om, at antibiotikabehandling altid bør kombineres med passende sanitære foranstaltninger. 
Extended and vaguely defined treatment periods present a risk from resistance perspective and would not be justifiable from a scientific point of view taking into account disease epidemiology as well as current awareness regarding the need to always combine antibiotic use with appropriate sanitary measures.
Tyskland aniMedica GmbH Im Südfeld 9 
Germany aniMedica GmbH Im Südfeld 9
Bulgarien Biovet JSC 39 Petar Rakov Str 4550 Peshtera Bulgarien 
Biovet JSC 39 Petar Rakov Str 4550 Peshtera Bulgaria
På grund af resistensudvikling gennem de senere tiår anses tylosin i dag ikke for at give tilstrækkelig virkning mod svinedysenteri (B. hyodysenteriae) og bør derfor ikke anvendes til denne sygdom. 
Due to resistance development through recent decades, tylosin is however today not considered to provide sufficient efficacy against swine dysentery (B. hyodysenteriae), and the substance should thus not be used for this disease.
Danmark Ceva Animal Health A/S Ladegårdsvej 2 
Denmark Ceva Animal Health A/S Ladegårdsvej 2
43206 Reus (Tarragona) Spanien 
43206 Reus (Tarragona) Spain
For størstedelen af de orale produkter indeholdende tylosin er det som nævnt lang tid siden, at de blev godkendt i EU's medlemsstater i henhold til de daværende godkendelseskrav. 
As previously mentioned, most oral tylosin products were authorised in the EU Member States long time ago according to marketing authorisation requirements at that time.
Bulgarien Zavet JSC 5 Kiril i Metodii Str. Zavet 
Zavet JSC 5 Kiril i Metodii Str. Zavet
Liste over veterinærlægemidlernes navne, lægemiddelformer, styrker, måldyrearter og indehavere af markedsføringstilladelse i medlemsstaterne 
List of the names, pharmaceutical forms, strengths of the veterinary medicinal products, animal species, and marketing authorisation holders in the Member States
1854 - 47020 Longiano (FC) Italien 
1854 - 47020 Longiano (FC) Italy
Spanien Elanco Valquímica, S.A. Avda. 
Elanco Valquímica, S.A. Avda.
I svenske stammer indsamlet i perioden 1990-2010 var resistensandelen noget lavere, men for over 75 % af isolaterne var den mindste hæmmende koncentration (MIC) langt over den foreslåede epidemiologiske afskæringsværdi på >16 μg/ml (Pringle et al. (2012)) 
Although a somewhat lower rate of resistance was noted in Swedish strains collected during 1990-2010, more than 75% of the isolates demonstrate a minimum inhibitory concentration (MIC) far above the proposed epidemiological cut-off value of >16 μg/ml (Pringle et al. (2012))
2730 HERLEV Danmark 
2730 HERLEV Denmark
Desuden viser nyere data, at der er meget høj in vitro-resistens mod makrolider af isolater fra EU af Brachyspira hyodysenteriae (det ætiologiske agens ved svinedysenteri), og at tylosin muligvis ikke længere er effektivt mod denne patogen. 
Additionally, recent data show that in vitro resistance to macrolides for isolates from the European Union of Brachyspira hyodysenteriae (the causative agent of swine dysentery) is very high and tylosin might no longer be effective against this pathogen.
Det vedgås, at mange af de orale formuleringer af tylosin til svin, der er på markedet i EU, blev godkendt for mange år siden i henhold til, hvad der dengang ansås for acceptable normer for begrundelse af dosering, og i forbindelse med de dengang acceptable strategier for brug af antibiotika. 
It is acknowledged that many oral tylosin formulations for pigs currently available on the EU market have been authorised many years ago, according to posology justification standards regarded acceptable at that time and in the context of what was then regarded as acceptable strategies for the administration of antimicrobials.
Resistenssituationen er ikke er undersøgt i alle lande, hvor tylosin anvendes mod svinedysenteri, men den hurtige udvikling af resistens over for tylosin sammen med in vitro-data for mange feltisolater fra forskellige områder lader konkludere, at der ikke kan forventes tilstrækkelig virkning til at berettige en indikation til behandling og forebyggelse af denne sygdom. 
Although the resistance situation has not been investigated in every country where tylosin is used against swine dysentery, the awareness that tylosin resistance develops quickly and the bulk of in vitro data covering many field isolates from different areas provide sufficient information to conclude that it cannot be expected that the efficacy rate is sufficient to warrant an indication for treatment and prevention of this disease.
Begrænsning af oral anvendelse af tylosin til svin til højst tre uger vil mindske risikoen for selektion af resistente organismer uden at hindre effektiv brug af produkterne til de i dag godkendte og forsvarlige indikationer. 
To limit the administration of oral tylosin to pigs to a maximum of three weeks would reduce the risk for selection of resistance without hampering the effective use of these products against currently authorised and justifiable indications.
Polígono Industrial de Alcobendas 28108 Alcobendas (Madrid) Spanien 
28108 Alcobendas (Madrid) Spain
Hvor det er relevant, slettes anbefalinger om dosisreduktion efter en indledende behandlingsperiode med højere dosis. 
Delete, where applicable, any recommendation to reduce the dose after an initial treatment period with a higher dose.
Rumænien Anupco LTd. Crockatt Road Lady Lane Industrial Estate, Hadleigh 
Crockatt Road Lady Lane Industrial Estate, Hadleigh
D-48308 Senden-Bösensell Tyskland 
D-48308 Senden-Bösensell Germany
Risikoen ved at udskyde initiering af effektiv behandling, indtil følsomhedsbestemmelsen foreligger, anses ikke for at opveje fordele ved muligheden for vellykket anvendelse af tylosin i enkelte tilfælde. 
The risk connected with delaying the initiation of effective treatment by the time required for susceptibility testing is not considered to outweigh the benefit related to the possibility to successfully use tylosin in a few cases.
• da de fleste orale formuleringer af tylosin til svin er godkendt med en anbefaling om behandling i op til tre uger, konkluderede CVMP, at denne maksimale behandlingsperiode vil give tilstrækkelig virkning. 
• most oral tylosin formulations for pigs are authorised with a recommendation to treat for up to three weeks, the CVMP concluded that this maximum duration of treatment would provide sufficient efficacy.
• i henhold til nyligt publicerede følsomhedsdata vil tylosin ikke have tilstrækkelig virkning mod B. hyodysenteriae, hvorfor CVMP konkluderede, at indikationen svinedysenteri ikke længere kan opretholdes, 
• according to recent published susceptibility data tylosin will not be sufficiently effective against B. hyodysenteriae and therefore the CVMP concluded the indication in swine dysentery can no longer be maintained;
Bulgarien Pharma Vet 40 Otec Paisii Str. 
Pharma Vet 40 Otec Paisii Str. Shumen
Kosynierów Gdyńskich 13-14 66-400 Gorzów Wielkopolski Poland 
66-400 Gorzów Wielkopolski Poland
Der er efterhånden større viden om risikoen for antimikrobiel resistens, og der er stigende bevidsthed om, at doseringen bør vælges med det dobbelte formål at administrere antimikrobielle stoffer længe nok til at opnå tilstrækkelig virkning, men at undgå unødvendig eksponering, der fremmer resistensudvikling. 
The knowledge regarding antimicrobial resistance risks has increased over time, and there is also an increasing focus on accommodating dosing strategy to the double aim of administering antimicrobials as long as necessary to obtain sufficient treatment effect, but to avoid unnecessary exposure that would encourage resistance development.
ZOOPAN Produtos Pecuários S.A. Rua da Liberdade, n° 77 2050-023 Aveiras de Baixo Portugal 
Rua da Liberdade, n° 77 2050-023 Aveiras de Baixo Portugal
I en undersøgelse af den antimikrobielle følsomhed af B. hyodysenteriae isoleret fra 21 polske brug konkluderedes det, at den laveste antimikrobielle aktivitet blev påvist for tylosin og lincomycin med hæmmende koncentrationer på hhv. >128 μg/ml og 32 μg/ml, (Zmudzki et al. (2012)) 
In a study of antimicrobial susceptibility of B. hyodysenteriae isolated from 21 Polish farms it was concluded that the lowest antimicrobial activity was demonstrated for tylosin and lincomycin, with inhibition of bacterial growth using concentrations >128 μg/ml and 32 μg/ml, respectively (Zmudzki et al. (2012)) 7.
Hvis der er angivet en behandlingsvarighed ud over tre uger eller der ikke er angivet behandlingsvarighed, erstattes angivelsen med følgende erklæring: Behandlingsvarigheden må ikke være over 3 uger. 
Replace, where applicable, treatment recommendations which are extended beyond 3 weeks, or where no treatment duration recommendation is given, with the following statement: Treatment duration should not exceed 3 weeks.
Med den meget høje resistensandel anses det ikke for tilstrækkeligt blot at indsætte advarsler eller forholdsregler om, at behandling af svinedysenteri med tylosin altid bør være baseret på følsomhedsbestemmelse. 
Given the very high resistance rate it is not regarded a sufficient measure to only include warning or precaution statements indicating that treatment of swine dysentery with tylosin should always be based on susceptibility testing.
Forudsat at svinedysenteri slettes fra indikationerne for orale formuleringer af tylosin til svin, og den maksimale behandlingsperiode indskrænkes til tre uger, kan benefit/risk-forholdet for disse produkter fortsat anses for at være positivt. 
Provided swine dysentery is excluded from the indications of oral tylosin formulations for pigs and the maximum treatment is restricted to three weeks, the benefit-risk balance of these products could continue to be regarded as positive.
Samlet resumé af den videnskabelige vurdering af veterinærlægemidler, der indeholder tylosin til oral administration gennem foderet eller drikkevandet til svin (se bilag I) 
Overall summary of the scientific evaluation of veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs (see Annex I)
20884 Sulbiate (MB) Italien 
20884 Sulbiate (MB) Italy
1000 Brussel Belgien 
1000 Brussel
Frankrig Lilly Frankrig S.A.S. 
Lilly France S.A.S.
For granulat- og pulver af tylosin til iblanding i drikkevandet til svin er den anbefalede behandlingsperiode kun undtagelsesvis over tre uger, uanset indikationen. 
Similarly, with regard to tylosin granules and powders aimed to be mixed in the drinking water for pigs the recommended treatment period is only in exceptional cases extended beyond 3 weeks independent of indication.
47032 Bertinoro (FC) Italien 
47032 Bertinoro (FC) Italy
Spanien LABORATORIOS HIPRA, S.A. Avda. 
LABORATORIOS HIPRA, S.A. Avda.
Måske delvis som følge heraf er der i dag betydelig variation mellem den anbefalede behandlingsvarighed for produkter til samme indikation og samme orale formulering til svin. 
Possibly in part due to this, currently for the same indication and the same oral formulation there is significant variation between products regarding the recommended treatment duration for pigs.
Tyskland Lilly Deutschland GmbH Abt. Elanco Animal Health Werner-Reimers-Straße 2-4 
Germany Lilly Deutschland GmbH Abt. Elanco Animal Health Werner-Reimers-Straße 2-4
58-260 Bielawa 
Dzierżoniowska 21 58-260 Bielawa Poland
• CVMP fandt det overordnede benefit/risk-forhold positivt for veterinærlægemidler indeholdende tylosin til oral administration gennem foderet eller drikkevandet til svin under forudsætning af ændringer af produktinformationen, 
• the CVMP considered that the overall benefit-risk balance is positive for veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs subject to amendments in the product information;
Ud fra hensynet dels til virkning, dels risiko for resistensudvikling, anses der for passende med en maksimal behandlingsperiode på tre uger med samme dosisniveau i hele behandlingsperioden, uanset sygdommens art, 
Taking efficacy aspects as well as the risk for resistance emergence into account, a maximum treatment period of three weeks applying the same dose level throughout the treatment period is regarded appropriate independent of disease;
Tyskland Kon-Pharma GmbH Senator-Bauer-Str. 34 
Germany Kon-Pharma GmbH Senator-Bauer-Str. 34
108.18 g/110 g Pulver til oral opløsning 
108.18 g/110 g Powder for oral solution
Industrial Agro-Reus c/ Prudenci Bertrana 5. 
ANDRES PINTALUBA, S.A. Pol. Industrial Agro-Reus c/ Prudenci Bertrana 5.
Kroatien GENERA d.d. 
GENERA d.d.
anbefalede CVMP ændring af markedsføringstilladelserne for veterinærlægemidler indeholdende tylosin til oral administration gennem foderet eller drikkevandet til svin (se bilag I) med henblik på de anbefalede ændringer i produktresuméerne, etiketteringen og indlægssedlerne, der fremgår af bilag III. 
the CVMP recommended variations of the marketing authorisations for veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs (see Annex I) in order to amend the summaries of product characteristics, labelling and package leaflets in line with recommended changes in the product information as set out in Annex III.
Zone Industrielle d'Etriché, 49500 Segré, Frankrig 
Lithuania Franvet, Zone Industrielle d'Etriché, 49500 Segré, France
Det er almindelig anerkendt, at antimikrobiel behandling altid må kombineres med hensigtsmæssige sundhedsmæssige foranstaltninger på bedriften for at forhindre yderligere spredning af en given mikroorganisme og begrænse risikoen for nye kliniske tilfælde. 
The general acceptance of the fact that antimicrobial treatment needs always to be combined with appropriate management and sanitary measures on the farm, to prevent the further spread of any particular microbe and thus reduce the risk for new clinical cases, makes it difficult to defend a need for very long treatment periods.
Frankrig SOGEVAL 200 AVENUE DE MAYENNE ZONE INDUSTRIELLE DES TOUCHES 53000 LAVAL 
200 AVENUE DE MAYENNE ZONE INDUSTRIELLE DES TOUCHES
Tyskland KLAT-Chemie GmbH Visbeker Str. 12 
Germany KLAT-Chemie GmbH Visbeker Str. 12
Riudoms (Tarragona) Spanien 
Riudoms (Tarragona) Spain
RIUDOMS (Tarragona) Spanien 
RIUDOMS (Tarragona) Spain
Indikationen behandling af svinedysenteri forårsaget af Brachyspira hyodysenteriae 
Indication for treatment of swine dysentery caused by Brachyspira hyodysenteriae
de la Industria, nº 30 
de la Industria, nº 30 Polígono Industrial de Alcobendas
Bulgarien Pharma SIS 4 San Stefano Str. 
Pharma SIS 4 San Stefano Str. Dobrich
Spanien MEVET, S. A.U. 
MEVET, S. A.U.
40 000 000 IU (50g) Pulver til oral opløsning 
40 000 000 IU (50g) Powder for oral solution
20864 Agrate Brianza (MB) Italien 
20864 Agrate Brianza (MB) Italy
Videnskabelige konklusioner og begrundelse for ændring af produktresuméerne, etiketteringen og indlægssedlerne 
Scientific conclusions and grounds for amendment of the summaries of product characteristics, labelling and package leaflets
Rumænien S.C. PASTEUR -FILIALA FILIPESTI Str. Principala, nr. 944 
S.C. PASTEUR -FILIALA FILIPESTI
Vanatyl-Pulver für Tiere Tylosin 
Vanatyl-Pulver für Tiere
SOGETYL 100 MUI POUDRE POUR SOLUTION BUVABLE POUR VEAUX PORCINS ET VOLAILLE 
SOGETYL 100 MUI POUDRE POUR SO LUTION BUVABLE POUR VEAUX PORCINS ET VOLAILLE
Langstrakt overforbrug kan være forklaringen på, at der i dag fra mange europæiske lande indberettes en høj resistensandel i stammer af B. hyodysenteriae, årsagen til svinedysenteri. 
The excessive use over time may explain the high proportion of resistance in B. hyodysenteriae strains, the cause for swine dysentery, reported from many European countries today.
20 g/100 g powder Premix til medicineret foder 
20 g/100 g powder Premix for medicated feeding stuff
Frankrig QALIAN 34 RUE JEAN MONNET ZI D'ETRICHE 49500 SEGRE Frankrig 
34 RUE JEAN MONNET ZI D'ETRICHE 49500 SEGRE France
En maksimal behandlingstid på tre uger for oralt tylosin til svin må derfor forventes at give tilstrækkelig behandlingsvirkning til de aktuelt godkendte indikationer for svin og vil desuden opfylde kravet om undgåelse af unødig eksponering og dermed risikoen for resistensudvikling. 
Thus, to state that the administration of oral tylosin for pigs should not exceed three weeks is likely to assure sufficient treatment efficacy for currently authorised indications in pigs and this measure would also satisfy the requirement to avoid unnecessary exposure and thus reduce the risk for resistance development.
4941 VX Raamsdonkveer Nederlandene 
4941 VX Raamsdonkveer The Netherlands
Tilsol 200, 200 g/1000g Tylosin 
Tilsol 200, 200 g/1000g
Hvis indikationerne for et produkt ikke angiver svinedysenteri, men heller ikke udelukker det, tilføjes følgende sætning i punkt 12: Der er påvist høj andel af in vitro-resistens i europæiske stammer af Brachyspira hyodysenteriae, hvilket er et tegn på, at produktet ikke vil være tilstrækkelig effektivt mod svinedysenteri. 
In case the indication(s) for a particular product do not specify swine dysentery, but do not exclude such use, the following sentence should be added to section 12: A high rate of in vitro resistance has been demonstrated in European strains of Brachyspira hyodysenteriae implying that the product will not be sufficiently efficacious against swine dysentery.
100 000 000 IU/jar Granulat til oral opløsning 
100 000 000 IU/jar Granules for oral solution
NL-4941 VX Raamsdonksveer Nederlandene 
NL-4941 VX Raamsdonksveer The Netherlands
20 g/100 g powder Pulver til oral opløsning 
20 g/100 g powder Powder for oral solution
Ændringer i de relevante afsnit af produktresuméet, etiketteringen og indlægssedlen 
Amendments in the relevant sections of the summary of product characteristics, labelling and package leaflet
Rumænien Chemifarma S.p.A. 
Lithuania Chemifarma S.p.A.
Danmark Elanco Animal Health A/S Eli Lilly Danmark A/S Lyskaer 3E, 2 tv. 
Denmark Elanco Animal Health A/S Eli Lilly Danmark A/S Lyskaer 3E, 2 tv.
08150 Parets del Valles (Barcelona) Spanien 
08150 Parets del Valles (Barcelona)
Den anbefalede maksimale behandlingsvarighed er imidlertid tre uger for de fleste orale formuleringer af tylosin til svin uanset indikation, hvilket tyder på, at denne behandlingsperiode i mange tilfælde er fundet tilstrækkelig. 
It is however acknowledged that, regardless of the indication, for most oral tylosin formulations authorised for pigs at present the maximum recommended treatment duration is three weeks, indicating that this has in many cases been concluded to be a sufficient treatment period.
I CVMP's oplæg om anvendelse af makrolider, lincosamider og streptograminer (MLS) hos fødevareproducerende dyr i EU: resistensudvikling og betydningen heraf for menneskers og dyrs helbred (EMA/CVMP/SAGAM/741087/2009) 
In the CVMP reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in foodproducing animals in the European Union: development of resistance and impact on human and animal health (EMA/CVMP/SAGAM/741087/2009)